Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.
IPO Year: 1999
Exchange: NYSE
Website: agilent.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/10/2025 | $135.00 → $145.00 | Underweight → Equal Weight | Barclays |
| 8/28/2024 | $157.00 | Overweight | Wells Fargo |
| 7/10/2024 | $135.00 → $150.00 | Neutral → Buy | Citigroup |
| 6/27/2024 | Outperform → Peer Perform | Wolfe Research | |
| 6/3/2024 | $135.00 | Hold | Jefferies |
| 4/5/2024 | $145.00 → $163.00 | Hold → Buy | Stifel |
| 12/13/2023 | $140.00 | Outperform | Wolfe Research |
| 12/12/2023 | $130.00 → $133.00 | Buy → Neutral | BofA Securities |
| 11/17/2023 | $163.00 → $125.00 | Buy → Neutral | UBS |
| 9/28/2023 | $123.00 | Mkt Perform | Bernstein |
Agilent Technologies Inc. (NYSE:A) today announced release of the new Seahorse XF Flex Analyzer, a high-performance, 24-well system designed to expand real-time metabolic analysis into optimized 3D tissue and organoid workflows, along with dedicated consumables and kit. Metabolism is vital for cellular functions, driving energy production and essential processes such as biosynthesis, adaptation, redox balance, mitochondrial function, and cell fate decisions. Disruptions in metabolism can lead to many diseases, making its analysis crucial for uncovering disease mechanisms and developing novel therapies. Interest in analyzing cellular metabolism in complex 3D biological models, such as tissu
LEWISVILLE, Ark., April 24, 2025 (GLOBE NEWSWIRE) -- Smackover Lithium, a Joint Venture ("JV") between Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLI) (NYSE:A) and Equinor, is pleased to announce that the brine production unit, now formally named the Reynolds Unit, for Phase I of its South West Arkansas ("SWA") Project has been unanimously approved by the Arkansas Oil and Gas Commission ("AOGC") with no objections or opposition in a hearing that was open to all stakeholders from the community. "We thank the AOGC for their due diligence in reviewing our application and for their swift approval," said Standard Lithium's President and COO, Dr. Andy Robinson, who prov
Agilent Technologies Inc. (NYSE:A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 in Chicago, Illinois. Innovative Agilent products and partnerships playing a crucial role in transforming cancer research, diagnostics, and therapeutics will be featured, including: Agilent Avida DNA Cancer Panels – Based on cutting-edge next-generation sequencing (NGS) target enrichment solutions that enable simultaneous DNA and methylation profiling from a single sample, the Avida product portfolio has expanded to include three new DNA panels*. Optimized based on the requirements of the European OncNGS Consortium, these catalog p
LEWISVILLE, Ark., April 21, 2025 (GLOBE NEWSWIRE) -- Smackover Lithium, a Joint Venture ("JV") between Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLI) (NYSE:A) and Equinor, is proud to announce that its South West Arkansas ("SWA") Project has been selected as one of the first critical mineral production projects to be advanced under Executive Order 14241, Immediate Measures to Increase American Mineral Production, issued on March 20, 2025, by President Trump. This prestigious designation, announced by the Federal Permitting Improvement Steering Council at the recommendation of the National Energy Dominance Council, underscores the project's strategic importance to na
European certification for PD-L1 IHC 22C3 pharmDx to help gastric or GEJ adenocarcinoma patients for KEYTRUDA® therapy Agilent Technologies Inc. (NYSE:A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR certification for the use as a Companion Diagnostic (CDx) to aid in the identification of gastric or gastroesophageal Junction (GEJ) adenocarcinoma patients who may be eligible for treatment with KEYTRUDA® (pembrolizumab)1. PD-L1 IHC 22C3 pharmDx (Code SK006) is approved for exclusive use with the Agilent Autostainer Link 48 advanced staining solution. KEYTRUDA is an anti-PD-1 therapy developed by Merck (known as MSD outside the United States and Cana
Agilent Technologies Inc. (NYSE:A) will release financial results for the second quarter of fiscal year 2025 after the stock market closes on Wednesday, May 28. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PDT on the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's investor relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Ag
Innovative technology supports testing of accuracy and reliability in Autolus Therapeutics' recently approved CAR T therapy AUCATZYL® Agilent Technologies Inc. (NYSE:A) is pleased to announce its role in supporting Autolus Therapeutics' FDA approval for AUCATZYL®, a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the xCELLigence Real-Time Cell Analysis (RTCA) technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required f
Agilent Technologies Inc. (NYSE:A) is excited to announce its participation at the upcoming United States and Canadian Academy of Pathology (USCAP) Conference, which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzing tissue samples, often for diagnosing diseases such as cancer. In collaboration with Hamamatsu, PathAI, Proscia, and Visiopharm, Agilent has developed an innovative end-to-end digital pathology workflow. This solution integrates AI-driven precision pathology software
Scientist recognized for pioneering advances in bioprocess development and biomanufacturing Agilent Technologies Inc. (NYSE:A) today announced that Columbia University has received an Agilent Research Catalyst (ARC) Award on behalf of Dr. Pawel Muranski, an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of
Field-Pilot DLE Facility Exceeds Key Performance Criteria to Confirm Engineering Design for South West Arkansas Project Large Volumes of DLE Product Sent to Third Party Vendors for Conversion to Battery-Quality Lithium Carbonate – These Samples Will Be Used in the Qualification Process With Potential Off-Take Partners LEWISVILLE, Ark., March 11, 2025 (GLOBE NEWSWIRE) -- Smackover Lithium, a Joint Venture ("JV") between Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLI) (NYSE:A) and Equinor, has achieved one of the last technical milestones in the development of the South West Arkansas ("SWA") project located in Lafayette and Columbia Counties, Arkansas. The JV, i
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
10-Q - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
DEFA14A - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
SCHEDULE 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
DEFA14A - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
DEF 14A - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
Barclays upgraded Agilent from Underweight to Equal Weight and set a new price target of $145.00 from $135.00 previously
Wells Fargo initiated coverage of Agilent with a rating of Overweight and set a new price target of $157.00
Citigroup upgraded Agilent from Neutral to Buy and set a new price target of $150.00 from $135.00 previously
Wolfe Research downgraded Agilent from Outperform to Peer Perform
Jefferies resumed coverage of Agilent with a rating of Hold and set a new price target of $135.00
Stifel upgraded Agilent from Hold to Buy and set a new price target of $163.00 from $145.00 previously
Wolfe Research initiated coverage of Agilent with a rating of Outperform and set a new price target of $140.00
BofA Securities downgraded Agilent from Buy to Neutral and set a new price target of $133.00 from $130.00 previously
UBS downgraded Agilent from Buy to Neutral and set a new price target of $125.00 from $163.00 previously
Bernstein initiated coverage of Agilent with a rating of Mkt Perform and set a new price target of $123.00
Agilent Technologies Inc. (NYSE:A) will release financial results for the second quarter of fiscal year 2025 after the stock market closes on Wednesday, May 28. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PDT on the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's investor relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Ag
Delivers solid Q1 results, confirms core growth and EPS for 2025 fiscal year First-quarter fiscal year 2025 Revenue of $1.68 billion for the first quarter ended Jan. 31, 2025, representing growth of 1.4% reported and up 1.2% on a core(1) basis compared with the first quarter of 2024. GAAP net income of $318 million; earnings per share (EPS) of $1.11, down 6% from the first quarter of 2024. Non-GAAP(2) net income of $377 million; EPS of $1.31, up 2% from the first quarter of 2024. Outlook for full 2025 fiscal year and Q2 Full-year revenue outlook is now in the range of $6.68 billion to $6.76 billion, representing a range of up 2.6% to 3.8% reported and 2.5% to 3.5% core(1).
Agilent Technologies, Inc. (NYSE:A) today announced a quarterly dividend of 24.8 cents per share of common stock. The quarterly dividend will be paid on April 23, 2025, to all shareholders of record as of the close of business on April 1, 2025. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted a
Agilent Technologies Inc. (NYSE:A) will release financial results for the first quarter of fiscal year 2025 after the stock market closes on Wednesday, Feb. 26. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PST. To join the listen-only conference call webcast, click the link on the Events section of Agilent's investor relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full
Delivers solid results in Q4; initiates FY25 guidance Fourth-quarter fiscal year 2024 Revenue of $1.70 billion, up 0.8% reported and down 0.3% core(1) from the fourth quarter of 2023. GAAP net income of $351 million; earnings per share (EPS) of $1.22, down 25% from the fourth quarter of 2023. Non-GAAP(2) net income of $418 million; EPS of $1.46, up 6% from the fourth quarter of 2023. Full fiscal year 2024 Revenue of $6.51 billion, down 4.7% on a reported basis and down 4.7% core(1) year-over-year. GAAP net income of $1.289 billion; EPS of $4.43, up 6% year-over-year. Non-GAAP(2) net income of $1.539 billion; EPS of $5.29, down 3% year-over-year. Fiscal year 2025 an
Agilent Technologies, Inc. (NYSE:A) today announced the company has increased its quarterly dividend to 24.8 cents per share of common stock, a 5% increase over the previous dividend. The quarterly dividend will be paid on Jan. 22, 2025, to all shareholders of record as of the close of business on Dec. 31, 2024. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includ
Agilent Technologies Inc. (NYSE:A) will release financial results for the fourth quarter of fiscal year 2024 after the stock market closes on Monday, Nov. 25. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PST. To join the listen-only conference call webcast, click the link on the Events section of Agilent's investor relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range
Agilent Technologies, Inc. (NYSE:A) today announced a quarterly dividend of 23.6 cents per share of common stock will be paid on Oct. 23, 2024, to all shareholders of record as of the close of business on Oct. 1, 2024. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' m
Delivers better-than-expected performance; raises midpoint of guidance Highlights Revenue of $1.58 billion, down 5.6% reported and 4.4% core(1) from the third quarter of 2023. GAAP net income of $282 million; earnings per share (EPS) of $0.97, up 155% from the third quarter of 2023. Non-GAAP(2) net income of $385 million; EPS of $1.32, down 8% from the third quarter of 2023. Full-year revenue outlook revised at $6.450 billion to $6.500 billion. Fiscal year 2024 non-GAAP(3) earnings guidance also revised at a range of $5.21 to $5.25 per share. Fourth-quarter revenue outlook expected at $1.641 billion to $1.691 billion with non-GAAP(3) EPS of $1.38 to $1.42. Agilent Techno
Technology helps high-throughput labs operate more efficiently Agilent Technologies Inc. (NYSE:A) today announced it has acquired Sigsense Technologies, a San Francisco, California-based startup that uses artificial intelligence and power monitoring to help optimize lab operations. Financial terms of the acquisition were not disclosed. Sigsense technology is already available to Agilent customers through CrossLab Connect, a suite of digital applications—inventory management, service management, asset monitoring, smart alerts, and asset lifecycle analytics—that improve lab performance. Integrated into the Agilent CrossLab Connect asset monitoring solution, Sigsense's algorithm tracks i
Agilent Technologies Inc. (NYSE:A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 in Chicago, Illinois. Innovative Agilent products and partnerships playing a crucial role in transforming cancer research, diagnostics, and therapeutics will be featured, including: Agilent Avida DNA Cancer Panels – Based on cutting-edge next-generation sequencing (NGS) target enrichment solutions that enable simultaneous DNA and methylation profiling from a single sample, the Avida product portfolio has expanded to include three new DNA panels*. Optimized based on the requirements of the European OncNGS Consortium, these catalog p
Expands Agilent's end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing Agilent Technologies Inc. (NYSE:A) today announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722078870/en/A BIOVECTRA manufacturing facility (Photo: Business Wire) Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. The acquisition builds on Agilent's CDMO specializati
Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m
New instrument delivers the full power and capability of Agilent GCs in a compact design SANTA CLARA, Calif., May 23, 2024 /PRNewswire/ -- Agilent Technologies Inc. (NYSE:A) proudly announces the 8850 Gas Chromatograph (GC) System, a small single-channel GC that combines the legacy of the 6850 GC with the capability and system intelligence of the 8890 GC. With a focus on speed and intelligence, the 8850 GC stands poised to revolutionize labs across diverse markets, including energy, chemicals, food, and pharmaceuticals while reducing energy consumption up to 30%. Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9270251-agilent-unveils-8
New instrument delivers the full power and capability of Agilent GCs in a compact design Agilent Technologies Inc., (NYSE:A) proudly announces the 8850 Gas Chromatograph (GC) System, a small single-channel GC that combines the legacy of the 6850 GC with the capability and system intelligence of the 8890 GC. With a focus on speed and intelligence, the 8850 GC stands poised to revolutionize labs across diverse markets, including energy, chemicals, food, and pharmaceuticals, while reducing energy consumption by up to 30%. Modern labs face the seemingly contrasting goals of maximizing analytical capacity with limited bench space while reducing the overall environmental impact of their opera
Agilent Technologies Inc. (NYSE:A) today announced that Padraig McDonnell has assumed the role of Agilent CEO, effective immediately. His appointment is part of the company's CEO transition plan announced Feb. 21. McDonnell is the fourth CEO in Agilent's history and succeeds Mike McMullen, who will serve as an adviser until he retires Oct. 31. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240501393789/en/Padraig McDonnell (Photo: Business Wire) "It's an incredible honor to serve as CEO of this great company that impacts the world by advancing the quality of life," McDonnell said. "I'm proud of how we forge partnerships with our
SAN FRANCISCO, CA, June 22, 2021 (GLOBE NEWSWIRE) -- Fundbox, the financial platform for small businesses, announced today that it has appointed Hilliard Terry to its Board of Directors. Mr. Terry is an experienced executive leader, corporate board member and advisor to private equity backed portfolio companies. Mr. Terry currently serves on the board of directors of Umpqua Holdings Corporation (NASDAQ:UMPQ), a financial services company. He also serves on the board of directors of Upstart Holdings, Inc. (NASDAQ:UPST), a leading artificial intelligence consumer lending platform, and on the board of TLG Acquisition One Corporation (NYSE:TLGA), a special purpose acquisition company. "H
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc.(NYSE: A) is pleased to announce Allison Ballmer has been named the company’s new senior vice president of Strategy and Corporate Development, reporting to Agilent President and CEO Mike McMullen. Ballmer will lead the corporate development team in identifying, developing, and evaluating merger-and-acquisition plans globally, as well as program management of integrations. She also will lead enterprise strategy while collaborating with Agilent businesses groups to drive critical growth initiatives across the company. Ballmer will serve as a key member of the executive staff and as an adviser to the CEO to help shape th
DUBLIN, Jan. 11, 2021 /PRNewswire/ -- Aon plc (NYSE: AON), the leading global professional services firm providing a broad range of risk, retirement and health solutions, announced today that the Board of Directors has declared a quarterly cash dividend of $0.46 per share on outstanding Class A Ordinary Shares. The dividend is payable February 12, 2021 to shareholders of record on February 1, 2021. About Aon Aon plc (NYSE: AON) Aon is a leading global professional services firm providing a broad range of risk, retirement and health solutions. Our 50,000 colleagues in 120 countries empower results for clients by using proprietary data and analytics to deliver insights that reduce volatilit